Evidence map›Paper›PMID 38832766›Full record

ArticleMicrobiology spectrum2024

Host tracheal and intestinal microbiomes inhibit

Susana Tejeda-Garibay, Lihong Zhao, Nicholas R Hum, Maria Pimentel, Anh L Diep, Beheshta Amiri, Suzanne S Sindi, Dina R Weilhammer, Gabriela G Loots, Katrina K Hoyer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Susana Tejeda-GaribayQuantitative and Systems Biology, Graduate Program, University of California, Merced, Merced, California, USA.ORCID 0000-0002-8647-1983
Lihong ZhaoDepartment of Applied Mathematics, University of California, Merced, Merced, California, USA.
Nicholas R HumBiosciences and Biotechnology Division, Lawrence Livermore National Laboratories, Livermore, California, USA.
Maria PimentelDepartment of Molecular and Cell Biology, School of Natural Sciences, University of California, Merced, Merced, California, USA.
Anh L DiepQuantitative and Systems Biology, Graduate Program, University of California, Merced, Merced, California, USA.
Beheshta AmiriBiosciences and Biotechnology Division, Lawrence Livermore National Laboratories, Livermore, California, USA.
Suzanne S SindiDepartment of Applied Mathematics, University of California, Merced, Merced, California, USA.
Dina R WeilhammerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratories, Livermore, California, USA.
Gabriela G LootsBiosciences and Biotechnology Division, Lawrence Livermore National Laboratories, Livermore, California, USA.
Katrina K HoyerQuantitative and Systems Biology, Graduate Program, University of California, Merced, Merced, California, USA.ORCID 0000-0001-5443-0733

Funding

Defining the State of CD8+ and CD4+ T cells and the Effect of Antibiotic Treatment on Chronic States of Coccidioidomycosis DiseaseF31HL160203 · NHLBI · UNIVERSITY OF CALIFORNIA, MERCED · PI TEJEDA-GARIBAY, SUSANA · 2021 to 2023
$98k
ASUCM Academic Affairs Fellowships and Undergraduate Research Symposium (FURS)internal Lawrence National Livermore Directed Research and Development funds 22-ERD-010NHLBI NIH HHS F31 HL160203Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research F31HL160203The American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists fellowshipUniversity of California Office of the President Awards MRP-17-454959, VFR-19-633952
6 · The paper itself

Abstract

Coccidioidomycosis, also known as Valley fever, is a disease caused by the fungal pathogen IMPORTANCE: Coccidioidomycosis is caused by a fungal pathogen that invades the host lungs, causing respiratory distress. In 2019, 20,003 cases of Valley fever were reported to the CDC. However, this number likely vastly underrepresents the true number of Valley fever cases, as many go undetected due to poor testing strategies and a lack of diagnostic models. Valley fever is also often misdiagnosed as bacterial pneumonia, resulting in 60%-80% of patients being treated with antibiotics prior to an accurate diagnosis. Misdiagnosis contributes to a growing problem of antibiotic resistance and antibiotic-induced microbiome dysbiosis; the implications for disease outcomes are currently unknown. About 5%-10% of symptomatic Valley fever patients develop chronic pulmonary disease. Valley fever causes a significant financial burden and a reduced quality of life. Little is known regarding what factors contribute to the development of chronic infections and treatments for the disease are limited.

Indexed as

CoccidioidesGastrointestinal MicrobiomeTracheaAnimalsAnti-Bacterial AgentsBacteriaCoccidioidomycosisFemaleMiceMicrobiotaRNA, Ribosomal, 16SAnti-Bacterial AgentsRNA, Ribosomal, 16SantibioticsCoccidioideslung microbiota

Identifiers

PMID38832766
PMCPMC11218535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.